123 related articles for article (PubMed ID: 36245321)
1. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
[TBL] [Abstract][Full Text] [Related]
2. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion.
Shuman K; Palmer S; Anders B; Moore D; Ptachcinski J; Grgic T; Alexander M; Hill L; Sung AD; Armistead PM; Kennedy L; Shaw JR
Transplant Cell Ther; 2023 Jan; 29(1):36.e1-36.e5. PubMed ID: 36404519
[TBL] [Abstract][Full Text] [Related]
4. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
5. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
6. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
[TBL] [Abstract][Full Text] [Related]
7. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
[No Abstract] [Full Text] [Related]
8. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
10. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
12. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
14. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
15. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Efficacy of Generic Melphalan Is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Pai AA; Devasia AJ; Panetta JC; Mani S; Stallon Illangeswaran RS; Mohanan E; Balakrishnan B; Lakshmi KM; Kulkarni U; Aboobacker FN; Korula A; Abraham A; Srivastava A; Mathews V; George B; Balasubramanian P
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):130-135.e1. PubMed ID: 31791694
[TBL] [Abstract][Full Text] [Related]
18. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
